PRTCY — PureTech Health plc
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1782999 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2026-09-22
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 637,278,000 | 121,275,000 | 257,789,000 |
| Dec 2025 | — | — | — | — | 534,710,000 | 252,470,000 | 229,034,000 |
| Jun 2025 | — | — | — | — | 553,242,000 | 260,604,000 | 184,217,000 |
| Dec 2024 | — | — | — | — | 602,635,000 | 280,641,000 | 194,702,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-77,231,000
Inventory
—
Receivables
—
ST Investments
$24,829,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,659,000 | -98,525,000 | -109,739,000 | 534,710,000 | 229,034,000 | 312,073,000 | -85,131,000 |
| Dec 2024 | 4,315,000 | -136,095,000 | 53,510,000 | 602,635,000 | 194,702,000 | 414,707,000 | -134,369,000 |
| Dec 2023 | 750,000 | -146,201,000 | -65,697,000 | 693,973,000 | 235,742,000 | 464,066,000 | -105,917,000 |
| Dec 2022 | 2,090,000 | -197,806,000 | -50,354,000 | 702,647,000 | 155,058,000 | 542,220,000 | -178,792,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.02T | $1142.85 | — |
| JNJ | JOHNSON & JOHNSON | $617.01B | $256.03 | — |
| ABBV | AbbVie Inc. | $464.43B | $262.82 | — |
| MRK | Merck & Co., Inc. | $356.01B | $144.30 | — |
| NVS | NOVARTIS AG | $268.00B | $141.00 | — |
News headlines (Yahoo Finance, 1h cache)
Celea Therapeutics Presents SURPASS-IPF Phase 3 Trial Design and Statistical Considerations for Evaluating Clinical Trials in Idiopathic Pulmonary Fibrosis at the IPF Summit 2026
2026-09-30 11:00 · Yahoo
PureTech Health PLC (PTCHF) (H1 2026) Earnings Call Highlights: Cash Runway to 2028, Seaport's ...
2026-09-22 19:00 · Yahoo
PureTech Health H1 Earnings Call Highlights
2026-09-22 10:03 · Yahoo
PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplast
2026-09-21 06:00 · Yahoo
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
2026-09-09 17:13 · Yahoo
PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress
2026-08-25 11:05 · Yahoo
Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (
2026-08-25 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.